Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib With and Without Ramucirumab in TKI-naïve EGFR-Mutant Locally Advanced or Metastatic NSCLC
NCT03909334Phase 2Active, not recruiting
- Sponsor
- Xiuning Le
- Start
- Jul 2019
- Primary completion
- Dec 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ramucirumab in non-small cell lung cancer (NSCLC), sponsored by Xiuning Le. Started Jul 2019; status: active, not recruiting.
02
Drugs
ramucirumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03909334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03909334.